Retatrutide 20 mg — Research Consultation
Retatrutide 20 mg is the larger dose-strength research preparation of the triple-receptor agonist studied in the published metabolic-research literature. The molecule binds and activates three endogenous receptor classes (GLP-1, GIP, glucagon). The 20 mg strength reduces reconstitution frequency across extended pharmacology protocols. This page summarises the mechanism and links you into a Nour-led consultation.
What retatrutide is
Retatrutide is a synthetic peptide engineered to activate three receptor classes simultaneously: the GLP-1 receptor, the GIP receptor, and the glucagon receptor. Each receptor has its own well-characterised endogenous ligand and physiological role. Triple-agonist molecules are a research class distinct from single- or dual-receptor agonist research.
Why the 20 mg strength?
For researchers running extended pharmacology protocols, the 20 mg lyophilised preparation reduces the number of reconstitution cycles required across the protocol period. Total compound mass per vial is the only difference from the 10 mg strength — pharmacology, mechanism, and quality verification are identical.
What the published research covers
Published preclinical and early-phase clinical research describes retatrutide pharmacology, receptor-binding affinities at each of the three target receptors, and pharmacokinetic profiles in animal and human studies. Endpoints in the published literature span glucose homeostasis, hepatic lipid metabolism, and energy expenditure. The research base is small relative to single-receptor agonist research and is still evolving.
Quality verification
Lyophilised retatrutide 20 mg manufactured under ICH Q7 GMP standards, with independent HPLC verification at a US-based third-party laboratory. Peak-area purity ≥98% at λ=214 nm against pharmacopoeia reference standards. COA available through the in-chat consultation.
Common research questions
- Is retatrutide legal in the UAE?
- Retatrutide is classified as a research compound in the UAE and is sold through standard wellness-supply channels with VAT compliance applied to every dispatch.
- Is the 20 mg different from the 10 mg pharmacologically?
- No. Same molecule, same pharmacology, same mechanism, same quality verification. The only difference is total compound mass per vial, which affects how often the researcher needs to reconstitute fresh across the protocol period.
- What dosing does the published research describe?
- Published early-phase human pharmacology studies describe dose-titration schedules over multiple weeks, starting low and escalating gradually. The pharmacokinetic profile supports once-weekly administration in published protocols. Specific dosing depends on the research question — Nour can walk through the protocols in the chat.
- How long does a 20 mg vial last?
- Depends on the researcher's chosen protocol dose and frequency. At a once-weekly research dose of 2-4 mg, a 20 mg vial supports 5-10 administrations. Nour can walk through the reconstitution math in the chat.
- How is purity verified?
- HPLC peak-area purity (≥98%) at a US-based third-party laboratory. COA available through the chat.
- Shelf life and storage?
- Lyophilised retatrutide is ambient-temperature stable in transit; long-term storage of the lyophilised powder at -20°C protected from light; refrigerated post-reconstitution per the supplied protocol.
- How fast is delivery in the UAE?
- Same-day delivery within Dubai, next-business-day across the rest of the UAE.
- Can Nour help me decide between 10 mg and 20 mg?
- Yes. Tap "Start a research consultation". The choice depends on your protocol duration, dose schedule, and reconstitution preference — straightforward to work through in chat.
Peer-reviewed references
Related consultations
Further reading
Talk to Nour about your research protocol
Nour reads the peer-reviewed literature and walks you through what each compound is best suited for. English or Arabic, inside the chat.